Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1ra
Thus, the dual role of GLP-1RAs in reducing neurodegeneration by improving neuronal survival and modulating microglial activity, providing a potential therapeutic approach for neurodegenerative diseases (summarized in Fig
This reflects the state of play as of early 2026: States that cover GLP-1s for obesity treatment (fee-for-service): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, Washington approximately 13 states total as of January 2026
People are also anatomically disposed to NAION if they have a crowded optic disc
If we really want to make the biggest difference on the health of the nation, we have to make sure that the people who would benefit the most have access to medications that are being shown to be beneficial. CLARIFICATION (Oct